5 Scenarios for the Future of Cancer Treatment

The next decade of cancer treatment will be defined by five intersecting trajectories: the mainstream clinical integration of personalized mRNA cancer vaccines, the widespread deployment of AI-driven liquid biopsies for early disease detection, the operational shift toward artificial intelligence to guide precision medicine, the transition of advanced cancer from a terminal illness into an actively managed chronic disease, and the rising imperative of the "Cancer Groundshot" to achieve global health equity. Together, these developments promise to dismantle the traditional, highly reactive, one-size-fits-all approach to oncology, replacing it with a hyper-personalized, data-driven, and long-term care model designed to manage malignancies over a patient's lifespan.

Introduction: The Myth of the Single Cure and the New Era of Precision

To understand the future of oncology, one must first discard the most pervasive misconception in modern medicine: the hope for a singular "cure for cancer." This myth assumes that cancer is a monolithic disease - akin to polio or smallpox - waiting for a single, universal magic bullet to eradicate it from the human population. The biological reality is profoundly more complex. Cancer is an umbrella term encompassing more than 200 distinct diseases, each characterized by unique genetic drivers, mutational landscapes, and sophisticated immune-evasion tactics.

An accurate everyday analogy is to imagine the human body not as a single machine, but as a sprawling, highly regulated metropolis. In a healthy city, billions of citizens (cells) perform specific jobs, reproduce only when necessary to replace aging infrastructure, and self-destruct when they become damaged or corrupted. Cancer is not an invading foreign army; rather, it is a localized rebellion from within. A small faction of cells ignores the body's zoning laws, refuses to undergo programmed cell death (apoptosis), and begins to replicate uncontrollably. These rogue cells hoard local resources, build their own blood supply networks, and eventually suffocate the surrounding infrastructure. Furthermore, even within a single patient, a tumor is deeply heterogeneous. It constantly evolves, creating sub-clones that mutate to survive the chemical warfare deployed against them ¹²¹. Attempting to treat this dynamic, evolving rebellion with a single drug is akin to trying to extinguish every type of fire - from electrical sparks to chemical spills to forest infernos - with the exact same bucket of water.

The clinical approach has fundamentally shifted away from seeking a universal cure and toward mastering targeted, highly individualized biological warfare. This evolution was dramatically accelerated by the global response to the COVID-19 pandemic, which validated novel mRNA biotechnologies and digitized healthcare infrastructures at a pace previously thought impossible ¹². However, the urgency for innovation is dire. Global cancer incidence is projected to rise to 28.4 million new cases annually by 2040, and over 35 million by 2050 ³⁴. The future of oncology lies in reprogramming the patient's own immune system, decoding the molecular whispers of tumors before they form visible masses, and utilizing artificial intelligence to navigate datasets too vast for the human mind to comprehend. As these scientific marvels transition into clinical realities, the medical community must also grapple with the profound economic and systemic challenges they create, ensuring that the future of cancer care is accessible to all.

How are mRNA vaccines transitioning from COVID-19 to fighting tumors?

The successful development and global deployment of messenger RNA (mRNA) vaccines against SARS-CoV-2 was a monumental public health achievement that inadvertently unlocked a new frontier in clinical oncology. While it may appear to the public that mRNA technology was born out of the pandemic crisis, researchers have been meticulously laying the groundwork for over three decades ². Prior to 2020, the clinical application of mRNA therapeutics was severely hindered by the inherent instability of the molecule, making it difficult to store, and the challenge of delivering it safely into human cells without triggering severe, systemic immune responses ⁷. The pandemic forced unprecedented global investment, leading to key breakthroughs by scientists such as Dr. Katalin Karikó and Dr. Drew Weissman. Their refinement of lipid nanoparticles (LNPs) as a delivery vehicle and the chemical modification of mRNA allowed the molecule to evade immediate destruction by extracellular enzymes (RNases) and cross the cellular membrane ²⁷.

Following the success of SARS-CoV-2 vaccines, global research and development infrastructure pivoted heavily toward therapeutic applications. According to global clinical intelligence, approximately 70% of active mRNA vaccine preclinical and clinical trials worldwide are now focused on diseases beyond COVID-19. Within this non-COVID research space, oncology accounts for a substantial 31% of all active trials, while the remaining 69% target other infectious, genetic, and immune diseases ². This proves that the post-pandemic infrastructure is permanently reshaping cancer research.

The Science of Personalized Tumor Targeting

Today, the clinical infrastructure built to fight a virus is being rapidly repurposed to hunt and destroy tumors. The core philosophy of an mRNA cancer vaccine is both biologically elegant and computationally complex. If the body's immune system can be taught to recognize the distinct "spike protein" of a virus, it can theoretically be taught to recognize the unique mutated proteins - known as neoantigens - presented on the surface of a malignant tumor cell ¹⁸⁵. Unlike traditional preventative vaccines, the majority of mRNA cancer vaccines are therapeutic; they are administered to patients who have already been diagnosed with cancer to prevent recurrence and metastasis ¹¹⁰.

The process is highly bespoke. It begins with a surgical biopsy of the patient's tumor. Advanced next-generation sequencing (NGS) and bioinformatics tools are used to map the genetic mutations specific to that individual's cancer. Artificial intelligence algorithms then identify which of these mutations are most likely to produce neoantigens that the patient's T-cells can recognize ²¹¹. An mRNA blueprint coding for these specific neoantigens is synthesized and encased in a lipid nanoparticle. When injected, the mRNA instructs the patient's own antigen-presenting cells to produce these tumor-like proteins. This effectively trains the immune system's killer T-cells to hunt down and destroy any cell bearing that specific molecular signature ⁶.

Recent clinical trial results have sent shockwaves through the global oncology community. In the Phase IIb KEYNOTE-942 trial, Moderna and Merck tested their personalized mRNA vaccine candidate, Intismeran Autogene (mRNA-4157/V940), in combination with the checkpoint inhibitor pembrolizumab in patients with high-risk melanoma. The combination therapy resulted in a remarkable 44% to 49% reduction in the risk of recurrence or death compared to pembrolizumab alone, and an extraordinary 62% reduction in the risk of distant metastasis ¹⁷. The synergy is profound: the mRNA vaccine primes the immune cells to recognize the cancer, while the checkpoint inhibitor removes the molecular "brakes" that tumors exploit to hide from immune attacks ¹. Similar breakthroughs are emerging in pancreatic cancer, traditionally one of the most lethal and treatment-resistant malignancies. A trial of BioNTech's autogene cevumeran (BNT122) demonstrated that vaccine-induced immune cells persisted in some patients for up to four years, significantly delaying relapse and suggesting the development of long-lasting, tumor-specific T-cell memory ⁷.

Fascinatingly, researchers have also discovered that the immune priming generated by previous viral vaccinations might be leveraged in oncology. Scientists at the University of Florida and MD Anderson Cancer Center observed that patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of beginning cancer immunotherapy lived considerably longer than those who did not. The viral mRNA vaccine appears to prime the immune system in a powerful, nonspecific way, "waking up" natural defenses and enhancing the efficacy of targeted cancer drugs ⁸. In separate animal models, researchers demonstrated that injecting the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine directly into solid tumors tagged the tumor cells with viral antigens, allowing the pre-existing viral immune memory to attack and reduce the tumor's size ⁸.

The Manufacturing and Cost Barriers

Despite these clinical triumphs, the personalized nature of mRNA cancer vaccines presents staggering logistical and financial hurdles. Turning the body's own killer cells against cancer requires absolute precision. As researchers at the Technical University of Denmark note, if a therapy misses its target even slightly, killer cells meant to attack tumors could attack healthy tissue with deadly consequences ⁶. Therefore, the single biggest barrier to widespread adoption is no longer the fundamental science, but the complex, bespoke manufacturing process required for every individual patient ²⁶.

Currently, the production cost of a personalized mRNA vaccine averages between $100,000 and $200,000 per patient ²⁹. The process involves extensive cleanroom space, highly skilled labor, and rapid turnaround times - often taking weeks to synthesize the vaccine while the patient's disease may be rapidly progressing ²⁸¹⁸. The biopharmaceutical industry is actively seeking automated solutions to shrink these costs and timelines. Cytiva, for instance, has developed the Sefia cell therapy manufacturing platform, which aims to reduce required cleanroom space by 50% and increase labor productivity by up to 40% through automation, drastically cutting the time required for the cell expansion phase ¹⁸. Furthermore, advances in AI-driven digital design tools allow researchers to screen millions of neoantigen candidates virtually, dramatically reducing the time from target identification to a validated vaccine design from years to mere weeks ⁶. To bypass these costs entirely in lower-resource settings, researchers are also exploring "shared" or "off-the-shelf" RNA vaccines that target frameshift mutations common to the majority of individuals with a specific cancer subtype, which have shown efficacy in early animal models at a fraction of the cost ⁹.

The Patient Experience: The NHS Cancer Vaccine Launch Pad

Translating this complex science into everyday patient care requires novel healthcare infrastructure. The United Kingdom's National Health Service (NHS) has pioneered a model for this integration with the introduction of the Cancer Vaccine Launch Pad (CVLP), developed in partnership with Genomics England. Aiming to provide up to 10,000 patients with personalized cancer treatments by 2030, the CVLP serves as a national matchmaking platform to accelerate patient access to mRNA and immunotherapy trials ¹⁰¹¹¹².

For patients over the next 5 to 10 years, the experience will shift radically. Following a cancer diagnosis and the surgical removal of a primary tumor, a patient will undergo a routine blood test and tissue sampling to check their specific molecular profile ²². If deemed a match for an ongoing trial, their data is entered into the CVLP database. The system then navigates them to the nearest participating NHS hospital ¹⁰¹¹. This initiative has already seen successful recruitment drives, such as the South West Cancer Alliance matching patients to BioNTech's colorectal cancer trials, and the rollout of the SCOPE trial evaluating the iSCIB1+ vaccine (developed by Scancell) for advanced melanoma ¹²²²¹³. The iSCIB1+ vaccine utilizes a needle-free injection into the skin or muscle to target the gp100 protein on melanoma cells, with treatments continuing for up to two years ²². Through platforms like the CVLP, patients can expect that following surgery, their biological data will be seamlessly sequenced, an mRNA vaccine will be rapidly synthesized, and they will receive localized injections to essentially "vaccinate" them against the return of their own disease ¹⁰¹¹²².

What are liquid biopsies, and how do they catch cancer before symptoms appear?

The current clinical gold standard for diagnosing and staging cancer relies almost exclusively on surgical biopsies and histopathology - an invasive, time-consuming process that often only occurs after a patient has developed noticeable, debilitating symptoms ¹⁴. By the time these physical symptoms appear, the cancer has frequently progressed to advanced stages, significantly narrowing the window for curative treatment and drastically reducing long-term survival rates ¹⁴²⁵. The second major trajectory reshaping oncology is the rise of the liquid biopsy, a technology that promises to transform cancer detection from a reactive procedure triggered by illness to a proactive, continuous surveillance mechanism.

Reading Molecular Messages in the Bloodstream

A liquid biopsy involves the collection and comprehensive analysis of bodily fluids - most commonly blood, but also urine, cerebrospinal fluid, and saliva - to detect the faint, early molecular signatures of cancer ¹⁴¹⁵¹⁶. As tumors grow, they undergo constant cellular turnover. When cancer cells naturally die, are destroyed by the immune system, or actively secrete material to communicate with surrounding tissue, they release fragments of their genetic material into the bloodstream. These biomarkers include cell-free DNA (cfDNA), specifically the tumor-derived fraction known as circulating tumor DNA (ctDNA), whole circulating tumor cells (CTCs), and microscopic, lipid-bound bubbles called extracellular vesicles or exosomes ¹⁴¹⁵¹⁷.

To understand the immense challenge and promise of liquid biopsies, consider the analogy of a crumbling book. Traditional tissue biopsies require surgeons to physically locate the book (the tumor) and cut out an entire chapter to read it. A liquid biopsy, however, relies on finding torn, fragmented sentences (ctDNA and exosomes) that have washed into a rushing river (the bloodstream). The difficulty lies in the fact that these tumor fragments are incredibly sparse; in early-stage disease, ctDNA may constitute only 5% to 10% of the total cfDNA circulating in the blood, vastly outnumbered by the normal DNA shed by healthy cells ¹⁴. Furthermore, exosomes act as tiny biological couriers, carrying molecular "cargo" such as proteomics, transcriptomics, metabolomics, and lipidomics that mirror the internal environment of the tumor, making them a rich but highly complex target for decoding ¹⁵.

The Convergence of AI and Genomic Sequencing

Detecting these minute, highly degraded traces of cancer requires extraordinary analytical sensitivity. This is precisely where liquid biopsies intersect intimately with artificial intelligence (AI) and machine learning (ML). Cancer produces highly complex, high-dimensional, and non-linear multi-omic data ¹⁴¹⁵. Traditional statistical methods fundamentally struggle to differentiate the faint signal of a malignant mutation from the noisy background of normal, everyday cellular processes ¹⁴.

AI algorithms are being trained on vast global datasets to recognize the distinct, multivariate molecular "fingerprints" of various cancers ¹⁵. A landmark example of this convergence was recently demonstrated by researchers at the Johns Hopkins Kimmel Cancer Center. Brain cancers, such as glioblastoma, are notoriously difficult to detect via blood tests because the blood-brain barrier severely restricts the amount of ctDNA that escapes into the general circulation. Previous liquid biopsy approaches detected brain cancer less than 10% of the time ¹⁸. However, by utilizing an advanced machine learning approach that searched not only for specific DNA fragments but also for repeating structural patterns in the genome uniquely linked to brain cancer, the Johns Hopkins team successfully detected brain cancer in approximately 75% of patients across international cohorts ¹⁸.

Similarly, AI-assisted liquid biopsies utilizing whole-genome sequencing of plasma cfDNA have demonstrated 85% sensitivity and 85% specificity in identifying early-stage colorectal cancer ¹⁷. In breast cancer, supervised ML algorithms analyzing CTCs, tumor microenvironment cells, and cellular features in blood samples have achieved early detection accuracies approaching 98.8% ¹⁷.

Practical Takeaways for the Next Decade

For the general public, the advent of AI-assisted liquid biopsies over the next 5 to 10 years will likely materialize as routine, multi-cancer early detection (MCED) blood tests integrated seamlessly into annual physical exams ¹⁵³⁰. Rather than undergoing invasive procedures or exposing the body to regular radiation, a simple blood or urine draw could alert physicians to the presence of breast, lung, or colorectal cancer long before tumors are visible on low-dose computed tomography (LDCT) or MRI scans ¹⁷³⁰.

However, this clinical transition will not be without systemic friction. The implementation of these highly sensitive tests introduces the profound challenge of "indeterminate findings." Medical professionals will increasingly face scenarios where a liquid biopsy clearly flags a potential cancer signal, but traditional imaging cannot yet locate the microscopic tumor ³⁰. This diagnostic gray area requires the healthcare industry to develop entirely new patient pathways to manage severe psychological distress, determine insurance coverage guidelines for expensive, repeated follow-up testing, and mitigate the genuine risks of overdiagnosis, where slow-growing anomalies are treated unnecessarily ³⁰³¹. From a health economic perspective, however, liquid biopsies are highly compelling. Studies show that liquid biopsies cost between $149 and $187, compared to over $6,000 for MR mammography, presenting a massively scalable alternative for population-wide screening ³¹³².

Will Artificial Intelligence replace my oncologist, or just make them better?

The explosion of biological data generated by modern oncology - from genome sequencing and digital pathology to continuous electronic health records (EHRs) - has fundamentally outpaced the cognitive capacity of any single human physician ³³. On one hand, the medical community possesses unprecedented, granular insight into how cancer operates at the molecular level; on the other, physicians are overwhelmed by the sheer volume of data, leading to systemic burnout and fragmented patient care ³³¹⁹. Artificial intelligence is rapidly evolving from a theoretical research tool into an indispensable clinical assistant deployed across the entire continuum of cancer care: prevention, diagnosis, treatment selection, and survivorship ²⁰³⁶.

Transforming Clinical Workflows and Drug Discovery

AI's most immediate and visible impact is operational. Natural language processing (NLP) and large language models (LLMs) are being deployed as ambient scribes in consultation rooms, quietly transcribing patient-physician conversations and automatically generating structured clinical notes within EHRs ¹⁹³⁶. A recent study at the Vanderbilt-Ingram Cancer Center evaluated this technology using 50 complex breast cancer cases. The study found that AI-assisted clinical summaries were ranked by oncology specialists as significantly more faithful, complete, and succinct than those drafted by clinicians alone ²¹. By alleviating the crushing administrative burden, AI is paradoxically helping to restore the human touch to medicine, allowing oncologists to spend their limited time looking at their patients, assessing emotional well-being, and delivering compassionate care rather than staring at their computer screens ¹⁹.

In the realm of diagnostics, AI deep learning models are achieving superhuman accuracy and speed. AI algorithms are routinely used to analyze digital pathology slides and complex radiological scans, identifying subtle patterns indicative of malignancy that the human eye might easily miss ³⁶²². For example, AI tools have been developed to rapidly detect EGFR mutations directly from standard pathology slides, potentially reducing the need for costly and time-consuming genetic testing by more than 40%. This streamlines clinical decision-making, preserves limited tissue samples, and radically accelerates a patient's access to targeted therapies ²³.

Furthermore, deep learning models like AlphaMissense and AlphaGenome are revolutionizing the pharmaceutical pipeline. These AI platforms interpret genetic variations to identify which alterations are functional and linked to cancer, driving target identification and drug design ²³. The power of this approach was demonstrated by researchers at MIT, who used a deep learning model to screen a digital library of over 100 million compounds in mere days, discovering "halicin," a powerful new antibiotic. Similarly, companies like Exscientia have utilized AI to co-invent and advance oncology and immunology molecules into human clinical trials in just 18 months, compared to the industry average of 42 months ⁴⁰. Analysts predict AI could cut both timelines and development costs - which regularly exceed $2 billion per successful drug - by more than half ⁴⁰.

The Real Barriers: Data Silos and Human Resistance

Despite these technical triumphs, the path to mainstream AI integration is fraught with deeply entrenched systemic hurdles. As highlighted at recent health innovation summits in Europe, the biggest barrier to AI adoption in medicine is not the technology itself - it is institutional data infrastructure and human culture ⁴¹.

Data silos represent a massive roadblock across the life sciences value chain. Healthcare systems and research institutions frequently operate on legacy IT infrastructure built in the 1990s, where clinical records, R&D laboratory results, and vast genomic datasets are locked in separate, non-communicating databases ³³⁴¹⁴². Effective AI models are entirely dependent on the data they learn from; inconsistent data collection methods, lack of interoperability, and the reluctance of academic researchers to share data prior to publication severely limit the utility of AI algorithms ³³⁴⁰⁴². Moreover, there is a profound risk of "AI bias." If predictive models are trained exclusively on Western, high-income populations, they fail to account for the unique genetic diversity and endemic disease profiles of populations in regions like Africa and South Asia, rendering the AI inaccurate or dangerous in those contexts ²⁰⁴⁰⁴³.

Culturally, there is substantial hesitation within the medical community. AI models are often perceived as impenetrable "black boxes" lacking explainability ²². Clinicians are rightfully cautious of "AI hallucinations" - instances where an algorithm generates a highly confident but factually incorrect diagnosis or treatment recommendation ¹⁹. Without rigorous prospective validation in clinical trials, treating AI outputs as gospel could have devastating consequences for patients. Furthermore, experts warn of the dangers of "deskilling." As observed in gastrointestinal endoscopy studies, if specialists become overly reliant on AI to detect abnormalities like adenomas, their independent clinical diagnostic abilities may atrophy over time ³⁶.

Ultimately, over the next decade, AI will not replace the oncologist. Instead, the clinician of 2035 will be a highly skilled orchestrator of AI tools. AI will function as a powerful, tireless decision-support system - flagging clinical trial matches, predicting adverse events, outlining radiation target volumes, and drafting treatment plans - but the oncologist's role will shift toward complex ethical judgment, empathetic patient communication, and nuanced decision-making under uncertainty ³⁶⁴⁴.

Why are doctors starting to treat cancer more like diabetes or heart disease?

Historically, a cancer diagnosis triggered a rigid, binary clinical pathway: aggressive, immediate intervention aimed at a definitive cure, or, if the disease was too advanced, a rapid transition to palliative and end-of-life care ²⁴. Advanced, metastatic cancer was almost universally viewed as a rapid death sentence, with traditional systemic chemotherapy rarely extending a patient's life beyond a single year ²⁴. However, the landscape of oncology has been radically altered by the advent of precision targeted molecular therapies, immune checkpoint inhibitors, and highly advanced surgical techniques.

Today, an increasing number of patients with advanced, incurable cancers - such as specific subtypes of breast, lung, prostate, and blood cancers - are living for years, and sometimes decades, with persistent but clinically controlled disease ²⁴²⁵. This unprecedented survival success has birthed an entirely new demographic in modern medicine: the chronic cancer survivor. In the United Kingdom alone, the number of cancer survivors stands at around 3.5 million and is projected to reach 5.3 million by 2040 ²⁵. In the United States, the survivor population is expected to surge from 18 million in 2022 to an estimated 27 million by 2050 ²⁵.

The Paradigm Shift to Chronic Disease Management

As cancer outcomes improve globally, organizations including the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and leading oncology institutions are beginning to reclassify many forms of cancer as chronic diseases ²⁵. This categorization aligns cancer with conditions like diabetes, chronic heart failure, chronic kidney disease, or HIV/AIDS ²⁴²⁵. This is not a defeatist categorization, but rather a necessary operational and philosophical shift to address the long-term, complex realities of living with a malignancy.

Treating cancer as a chronic disease demands a fundamental restructuring of healthcare delivery systems. Currently, survivorship care is highly fragmented and inconsistently delivered ²⁵. Patients who have stabilized on long-term oral targeted therapies frequently fall into a clinical gray area between the highly specialized oncology clinic and their general primary care physician ²⁴. Rosalind Adam and colleagues, writing in The Lancet Oncology, argue that cancer reviews must be systematically integrated into routine chronic disease management within primary care. Doing so would improve the detection of primary cancers and recurrences, manage the cardiovascular risks associated with treatment, and utilize existing primary care infrastructures to monitor long-term outcomes ²⁵⁴⁷²⁶.

Managing the Long-Term Toxicities

For the patient of 2030, managing cancer will look increasingly like managing chronic heart disease or autoimmune disorders. It will require routine, non-invasive monitoring via liquid biopsies, regular adjustments to daily targeted medications, and the proactive management of long-term side effects ²⁴²⁵.

The toxicities associated with living for years on advanced, continuous therapeutics are profound and multifaceted. Physically, patients may endure chronic fatigue, peripheral neuropathy, endocrine disruption, and accelerated cardiovascular aging - side effects that are distinctly different from the acute nausea and hair loss associated with traditional cytotoxic chemotherapy ²⁴⁴⁷. Psychologically, patients must navigate the constant, underlying uncertainty of recurrence - a phenomenon commonly termed "scanxiety" - while dealing with the altered dynamics of their relationships and careers ²⁴.

Perhaps most pressingly, patients face severe "financial toxicity." The medical innovations keeping them alive, such as next-generation biologics, CAR-T cell therapies, or continued immune therapies, carry exorbitant price tags. For example, CAR-T cell therapies can cost over $1 million per patient, and targeted therapies like Trastuzumab (Herceptin) for HER2-positive breast cancer demonstrate Incremental Cost-Effectiveness Ratios (ICER) of roughly $62,000 per Quality-Adjusted Life Year (QALY) ⁴⁹. These compounding costs drain retirement savings, trigger bankruptcies, and severely strain national healthcare insurance models ²⁴²⁷. Integrating holistic cancer management into primary care will be essential to ensure patients receive comprehensive cardiovascular, psychological, and financial navigation alongside their oncological care, allowing them to truly live with, rather than just survive, their disease ²⁵⁴⁷.

What is the "Cancer Groundshot," and why does global health equity matter?

While discussions regarding the future of oncology in the West are dominated by multi-million-dollar AI models, $100,000 bespoke mRNA vaccines, and advanced radioligand therapies, a stark and uncomfortable reality persists: these innovations are heavily concentrated in High-Income Countries (HICs). Meanwhile, global cancer incidence is accelerating, projected to hit over 35 million new cases by 2050 - a 77% increase from 2022 ⁴. The heaviest human and economic toll will be exacted on Low- and Middle-Income Countries (LMICs), where up to 70% of all global cancer deaths are expected to occur ⁴.

The disparity in the global oncology workforce is staggering and severely limits the deployment of advanced care. According to 2025 data presented at the European Society for Medical Oncology (ESMO) Congress, an overwhelming 92.2% of the world's oncology workforce is concentrated in high- and upper-middle-income countries ²⁸. This translates to approximately 1 oncologist for every 256 new cancer cases annually in HICs. In stark contrast, low-income nations suffer from a ratio of 1 oncologist for every 7,160 new cases ²⁸.

The Groundshot Philosophy

In response to this extreme inequity, global health leaders have championed a strategic philosophy known as the "Cancer Groundshot" ³²⁹. The highly publicized narrative of the "Cancer Moonshot" prioritizes massive financial investments in ultra-advanced, high-cost technologies (like cellular therapies and personalized genomic sequencing) aimed at curing the most intractable cancers. While scientifically vital, these moonshots are virtually irrelevant to a patient in sub-Saharan Africa or rural India who lacks access to basic surgical care, functional pathology labs, or affordable generic chemotherapy ⁴⁵³.

The Cancer Groundshot demands a radical reprioritization of global resources. Its core principle dictates that the global community must ensure equitable access to interventions that are already proven to work before funneling the majority of health investments into novel interventions that only a fraction of the world can afford ³⁵³⁵⁴. The Groundshot emphasizes "low-hanging fruit": scaling up cervical cancer screening and HPV vaccination programs, implementing task-shifting (training mid-level providers and community health workers to deliver basic cancer care), expanding access to essential systemic therapies and safe surgical oncology, and investing in high-quality, reliable cancer registries to track local epidemiological data ⁴⁵⁴³⁰.

The Impact of COVID-19 on Global Care Infrastructure

The urgency of the Groundshot was exacerbated by the devastating impact of the COVID-19 pandemic. In LMICs, the diversion of already scarce medical resources to the pandemic response decimated fragile cancer care infrastructure. Immunization rates plummeted; in sub-Saharan Africa alone, an estimated 6.96 million fewer children were vaccinated against rotavirus, and 5.31 million went unprotected against pneumococcal disease, highlighting the collapse of routine primary care ³¹. In oncology specifically, diagnostic endoscopy volumes plummeted by 60% to 80% in many regions, causing widespread delays in diagnosis and leading to severe "stage migration" - where patients who would have been caught early presented with advanced, incurable disease ³²⁵⁸³³.

However, the pandemic also forced pragmatic, long-lasting innovations. To circumvent physical limitations and reduce hospital visits, there was a rapid global adoption of tele-oncology and hypofractionated radiotherapy. For instance, the use of ultra-hypofractionated breast cancer regimens (delivering 26 Gy in 5 fractions, rather than weeks of daily visits) increased from 0.2% of courses in April 2019 to 60.6% in April 2020 in certain areas ³³. Furthermore, the vaccine apartheid experienced during COVID-19 has spurred a powerful movement to build local vaccine and biologic manufacturing capacity in regions like Senegal, South Africa, and India (such as the Serum Institute of India), facilitated by technology transfer partnerships and ongoing debates over intellectual property waivers ⁶⁰³⁴³⁵.

Bridging the Divide: Innovations for the Global South

Looking toward 2035, the implementation of technology in LMICs must intentionally bypass the heavy, expensive infrastructure models of the West. Concepts like the proposed "OncoCheck" model offer a glimpse into this future. The model proposes combining point-of-care testing (POCT) with liquid biopsies and cloud-based AI to achieve high-sensitivity diagnostics in resource-limited settings ³¹³⁶. In regions where MRI machines and specialized pathologists are scarce, a community health worker could draw a patient's blood, process it on a portable microfluidic electrochemical biosensor, and use an AI-assisted smartphone app to detect cancer signatures at a fraction of the cost of traditional screening ³¹³⁶³⁷.

Policy, advocacy, and governance are also shifting as the Global South asserts its agency. In Brazil, civil society organizations like FEMAMA are leveraging AI tools and WhatsApp chatbots to prioritize genetic testing and speed up cancer referrals ³⁸. Recognizing the need to attract global research, the Brazilian government enacted Law No. 14.874/2024 to streamline ethical reviews and strengthen the regulatory environment for clinical trials, making its vast Unified Health System (SUS) more accessible to international sponsors ³⁹. This legislative push, combined with international partnerships - such as the recent collaborative agreement between Oxford University and the Brazilian Ministry of Health to advance AI models and cancer vaccines locally - demonstrates how emerging economies are refusing to be mere consumers of Western medicine, striving instead to become active hubs of global oncology innovation ³⁹⁴⁰⁶⁸. Similarly, India's National Cancer Grid has pioneered highly cost-effective treatment strategies, such as using ultra-low-dose nivolumab combined with metronomic chemotherapy for head and neck cancers, proving that high-value care can be achieved without bankrupting health systems ⁴.

Summarizing the 5 Trajectories of Future Oncology

The transition of these five trajectories from theoretical promise to standard clinical reality will vary significantly based on technological maturity, regulatory environments, cost barriers, and systemic readiness.

To further illustrate the economic implications driving the need for both the Moonshot and the Groundshot, the following data highlights the varying cost-effectiveness of modern oncology interventions, underscoring why health systems must balance high-cost innovations with scalable, proven therapies.

Bottom Line

The next decade of oncology promises an era of unprecedented, data-driven precision. The rapid acceleration of mRNA technology, supercharged by the pandemic response, has proven that the body's own immune system can be safely and effectively programmed to hunt down malignant cells based on an individual's unique genetic code. Paired with AI-driven liquid biopsies that can detect the complex molecular whispers of a tumor long before it takes physical root, the medical community is moving away from reactive, aggressive treatments toward proactive, systemic surveillance. Furthermore, as cancer increasingly transitions into a manageable chronic disease, patients will benefit from longer, higher-quality lives, supported by intelligent algorithms that assist oncologists in navigating incredibly complex molecular data while reducing administrative burdens.

However, the fundamental unknown remains socio-economic rather than scientific. The extraordinary costs of bespoke manufacturing, the complexities of managing indeterminate AI findings, and the profound persistence of institutional data silos threaten to stall these scientific miracles at the laboratory door. Most critically, the global oncology community faces a severe ethical reckoning. If the pragmatic principles of the "Cancer Groundshot" are not integrated robustly alongside these high-tech moonshots, the future of cancer care risks becoming a marvel of modern science that is accessible only to a privileged fraction of the global population. True victory over cancer will not be achieved by the discovery of a single cure, but by the equitable, global distribution of these powerful new biological and computational tools.